The company and its board of directors guarantee that the information disclosed is true, accurate, and complete, and contains no false representations, misleading statements, or material omissions.
Qingdao Baiyang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the eighth meeting of its fourth Board of Directors on June 10, 2026. The meeting deliberated and passed the proposals on formulating the draft Articles of Association and related rules of procedure applicable after the Company's H share offering and listing, revising and formulating certain corporate governance policies, and formulating the "Confidentiality and Archiving Management System for Overseas Issuance and Listing of Securities." The relevant matters are hereby announced as follows: